版本:
中国

BRIEF-Genmab: FDA grants priority review for daratumumab

Oct 10 Genmab A/S :

* U.S. FDA grants priority review for daratumumab in relapsed multiple myeloma

* The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of Feb. 17 to take a decision on daratumumab in this indication

* The PDUFA date for the combination of daratumumab with pomalidomide/dexamethasone is June 17, 2017 Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐